Next Article in Journal
Pulmonary Arterial Hypertension Induces a Distinct Signature of Circulating Metabolites
Next Article in Special Issue
Role of Arginase 2 in Murine Retinopathy Associated with Western Diet-Induced Obesity
Previous Article in Journal
Virtual Reality for PEripheral Regional Anesthesia (VR-PERLA Study)
Previous Article in Special Issue
Identification of Diagnostic and Prognostic microRNAs for Recurrent Vitreous Hemorrhage in Patients with Proliferative Diabetic Retinopathy
Open AccessReview

Do Genomic Factors Play a Role in Diabetic Retinopathy?

1
Department of Surgery/Ophthalmology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
2
New Mexico VA Health Care System, Albuquerque, NM 87131, USA
3
Translational and Genomics Research Institute (TGen), Phoenix, AZ 85004, USA
4
Department of Cell Biology & Physiology, UNM, Albuquerque, NM 87131, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 216; https://doi.org/10.3390/jcm9010216
Received: 9 December 2019 / Revised: 6 January 2020 / Accepted: 9 January 2020 / Published: 14 January 2020
(This article belongs to the Special Issue Diabetic Retinopathy: Biomolecules and Pathophysiology)
Although there is strong clinical evidence that the control of blood glucose, blood pressure, and lipid level can prevent and slow down the progression of diabetic retinopathy (DR) as shown by landmark clinical trials, it has been shown that these factors only account for 10% of the risk for developing this disease. This suggests that other factors, such as genetics, may play a role in the development and progression of DR. Clinical evidence shows that some diabetics, despite the long duration of their diabetes (25 years or more) do not show any sign of DR or show minimal non-proliferative diabetic retinopathy (NPDR). Similarly, not all diabetics develop proliferative diabetic retinopathy (PDR). So far, linkage analysis, candidate gene studies, and genome-wide association studies (GWAS) have not produced any statistically significant results. We recently initiated a genomics study, the Diabetic Retinopathy Genetics (DRGen) Study, to examine the contribution of rare and common variants in the development of different phenotypes of DR, as well as their responsiveness to anti-VEGF treatment in diabetic macular edema (DME). Our preliminary findings reveal a novel set of genetic variants involved in the angiogenesis and inflammatory pathways that contribute to DR progression or protection. Further investigation of variants can help to develop novel biomarkers and lead to new therapeutic targets in DR. View Full-Text
Keywords: diabetic retinopathy; genetics; GWAS; whole exome sequencing; blood-retinal barrier; VEGF diabetic retinopathy; genetics; GWAS; whole exome sequencing; blood-retinal barrier; VEGF
Show Figures

Figure 1

MDPI and ACS Style

Cabrera, A.P.; Monickaraj, F.; Rangasamy, S.; Hobbs, S.; McGuire, P.; Das, A. Do Genomic Factors Play a Role in Diabetic Retinopathy? J. Clin. Med. 2020, 9, 216.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop